Enveric Biosciences (ENVB) announced the issuance of its 23rd patent from the United States Patent and Trademark Office for novel compounds within its neuroplastogenic patent estate, further expanding its intellectual property assets for the potential treatment of mental health disorders. The patent, U.S. Patent No. 12,428,408, titled, “Fused Heterocyclic Mescaline Derivatives,” covers a unique series of compounds, which are designed to target key serotonin receptors and drive neuroplasticity.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Enveric hires firm to contest post-grant review petition filed by Gilgamesh
- Enveric Biosciences to explore digital asset treasury strategy opportunities
- Psychedelic: Enveric announces EB-003 manufacturing milestones
- Enveric Biosciences completes key manufacturing milestones for EB-003
- Enveric Biosciences files to sell 5.02M shares of common stock for holders